1. Jones RL, Lakhani SR, Ring AE, et al. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer. 2006; 94:358-362.
2. Burcombe RJ, Makris A, Richman PI, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005; 92:147-155.
3. Kong SY, Kang JH, Kwon Y, et al. Serum HER-2 concentration in patients with primary breast cancer. J Clin Pathol. 2006; 59:373-376.
4. Schippinger W, Regitnig P, Bauernhofer T, et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncol Rep. 2004; 11:1331-1336.
5. Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 2006; 6:2356-2362.